Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon levels. It is unique among DPP-4 inhibitors for its primary biliary excretion and lack of significant renal clearance.
## Primary Indications
Type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise to improve glycemic control.
## Adult Dosing
* **Standard Dose:** 5 mg orally once daily.
* **Maximum Dose:** 5 mg daily.
## Pediatric Dosing
* **Safety/Efficacy:** Not established for patients <18 years. Use is generally not recommended in the pediatric population.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is required for any degree of renal impairment (including end-stage renal disease).
* **Hepatic Impairment:** No dose adjustment is required.
## Contraindications
* History of hypersensitivity reaction to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions).
* Type 1 diabetes or treatment of diabetic ketoacidosis.
## Adverse Effects
* **Common:** Nasopharyngitis, hypoglycemia (when used with secretagogues like sulfonylureas or insulin).
* **Serious:** Acute pancreatitis (rare), severe and disabling arthralgia, bullous pemphigoid, and potential risk of heart failure (observed in DPP-4 class).
## Key Drug Interactions
* **CYP3A4/P-gp Inducers (e.g., Rifampin):** May decrease linagliptin plasma concentrations. If co-administration is necessary, monitor glycemic control closely.
* **Sulfonylureas/Insulin:** Increased risk of hypoglycemia; consider lowering the dose of the secretagogue.
## Monitoring
* **HbA1c:** Every 3–6 months.
* **Blood Glucose:** For patients utilizing insulin or secretagogues, monitor for hypoglycemia.
* **Clinical:** Observe for signs/symptoms of pancreatitis (persistent severe abdominal pain) or bullous pemphigoid (blistering or erosions).
## Clinical Pearls
* **Pharmacokinetics:** Unlike other DPP-4 inhibitors, linagliptin undergoes minimal renal excretion, making it ideal for patients with significant chronic kidney disease.
* **Administration:** May be taken with or without food.
* **Heart Failure:** Use caution in patients with known heart failure; monitor for new-onset dyspnea or edema.
* **Class Effect:** DPP-4 inhibitors are associated with immune-mediated skin reactions; discontinue if bullous pemphigoid is suspected.
***
*Disclaimer: This information is for educational purposes and does not replace professional clinical judgment. Always verify current prescribing information, institutional protocols, and local drug monographs before prescribing or administering medication.*
